Search

ntroduction The aim of this article was to investigate the impact of chronic antithrombotic therapy (AT) use on the time of detection of bladder cancer, assuming that patients taking AT experience episodes of macroscopic hematuria earlier, and therefore have a more favorable histopathological grade and stage, as well as a smaller number and size of tumors compared to patients not taking AT. Material and methods A retrospective, cross-sectional study was conducted, including 247 patients who underwent bladder cancer surgery for the first time at our institution during the three-year period (2019– 2021) and who experienced macroscopic hematuria. Results A lower frequency of high-grade bladder cancer (40.6% vs 60.1%, P = 0.006), T2 stage (7.2% vs 20.2%, P = 0.014), and a lower frequency of tumors larger than 3.5 cm (29% vs 57.9%, P

This study investigated the impact of the initial clinical presentation of bladder cancer on tumor characteristics. A cross-sectional, retrospective study was performed, and it involved 515 patients who underwent transurethral bladder cancer resection at the University Hospital Center Split between April 2019 and April 2023, excluding recurrent cases. The association between symptomatic versus asymptomatic presentation and bladder cancer characteristics was analyzed. A subgroup analysis compared tumor characteristics between patients with gross and microscopic hematuria. Multiple regression analyses revealed a significant association between symptomatic presentation and the detection of high-grade bladder cancer (OR 3.43, 95% CI 2.22–5.29, p < 0.001), concomitant CIS (OR 3.41, 95% CI 1.31–8.88, p = 0.012), T2 stage bladder cancer (OR 5.79, 95% CI 2.45–13.71, p < 0.001), a higher number of tumors (IRR 1.24, 95% CI 1.07–1.45, p = 0.005), and larger tumor size (B 1.68, 95% CI 1.19–2.18, p < 0.001). In the subgroup analysis, gross hematuria was associated with the detection of high-grade bladder cancer (OR 2.07, 95% CI 1.12–3.84, p = 0.020), T2 stage bladder cancer (OR 6.03, 95% CI 1.42–25.49, p = 0.015), and larger tumor size (B 1.8, 95% CI 0.99–2.6, p < 0.001). The identified associations between symptomatic presentation and unfavorable bladder cancer characteristics, likely attributed to early detection in asymptomatic cases, underscore the importance of additional research in the development of bladder cancer screening strategies.

Cilj istraživanja: Cilj ovog istraživanja je prikazati rezultate i istražiti uspješnost kombiniranog testa probira na kromosomopatije ploda u KBC Split. Materijali i metode: Provedeno je presječno retrospektivno istraživanje. Uključene su sve trudnice u kojih je proveden kombinirani test probira u Klinici za ženske bolesti i porode KBC Split od 1. siječnja 2011. do 31. prosinca 2017. godine. Podatci su prikupljeni iz digitalne arhive Zavoda za medicinsko laboratorijsku dijagnostiku i arhive Klinike za ženske bolesti i porode. Promatrani su sljedeći podatci: a) godina izvođenja kombiniranog testa, b) životna dob ispitanica, c) navršeni tjedan trudnoće, d) vrijednosti beta podjedinice humanog korionskog gonadotropina (β-hCG) iz periferne krvi majke, e) vrijednost proteina A udruženog s trudnoćom (engl. pregnancy associated protein A; PAPP-A) iz periferne krvi majke, f) vrijednost ultrazvučnog biljega nuhalne prozirnosti, g) vrijednosti a priori rizika od kromosomopatija ploda po životnoj dobi trudnice, h) vrijednosti rizika od kromosomopatija ploda izračunatog kombiniranim testom, i) indikacija za izvođenje amniocenteze (RACZ), j) prethodna provedenost kombiniranog testa u žena kojima je odobren prekid trudnoće iz eugeničkih ili medicinskih razloga, k) prethodna provedenost kombiniranog testa u žena koje su rodile dijete s kromosomopatijom. Rezultati: Udio probirnih testova na kromosomopatije ploda u ukupnom broju porođaja iznosio je 27,28%, a među njima je većinu činio kombinirani test (81,89%). Kombiniranom testu u istraživanom razdoblju pristupilo je 6898 trudnica. Najveći broj trudnica pripadao je dobnoj skupini od 30 do 35 godina (39,99%). Kombinirani test provodio se između 10. i 14. tjedna trudnoće, najviše u 12. tjednu (48,93%). Porastom životne dobi trudnice statistički se značajno povećava broj a priori visokorizičnih trudnica za trisomiju 21 po životnoj dobi, kao i po rezultatima kombiniranog testa (P, Objective: The aim of this study is to present the results, as well as to investigate the success rate of the combined first trimester screening for fetal chromosomal abnormalities in the University Hospital Centre of Split. Materials and methods: A retrospective cross-sectional study was carried out. The study involved all pregnant women who underwent combined first trimester screening for fetal chromosomal abnormalities in the University Hospital Centre of Split from January 1st 2011 to December 31st 2017. Relevant data was collected from the Department of Medical Laboratory Diagnostics digital archive, as well as from the Department of Gynecology and Obstetrics archive. The following data was taken into account: a) year in which the test was performed, b) age of the participants, c) gestational age, d) values of the beta subunit of human chorionic gonadotrophin (β-hCG) from the peripheral blood of the mother, e) values of the pregnancy associated protein A (PAPP-A) from the peripheral blood of the mother, f) values of the ultrasound marker nuchal translucency, g) values of a priori risk of fetal chromosomal abnormalities based on the age of the mother, h) values of risk of fetal chromosomal abnormalities calculated with the combined first trimester screening, i) indication for performing amniocentesis, j) previous implementation of the combined first trimester screening in women to whom abortion was approved for eugenic or medical reasons, k) previous implementation of the combined first trimester screening in women who bore a child with chromosomal abnormalities. Results: The amount of screenings for fetal chromosomal abnormalities in the total number of births was equivalent to 27.28%, and most of those screenings were in fact combined first trimester screenings (81.89%). A total of 6898 pregnant women underwent the combined first trimester screening in the research period. Most women were between 30 and 35 years of age (39.99%). The combined screening was performed between the 10th and the 14th week of pregnancy, mostly in the 12th week (48.93%). With the increase of a patient’s age, a statistically significant increase in the number of pregnant women who were a priori at high risk for trisomy 21 based on age, as well as on the combined test results was detected (P